Developing new DNA products for HIV treatment and prevention
Official title: Administrative Core
Funded at Wistar Institute · NIH-11011257 · Data updated 2026-11-12
This study is working on new DNA products to help improve treatments and vaccines for HIV, which could lead to better options for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 8, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $697,854 |
| NIH project number | 5U19AI166916-03 |
| Project ID | NIH-11011257 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit include individuals at risk for HIV or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV and do not have the virus may not receive direct benefits from this research.
What this research studies
This research focuses on creating and managing new synthetic DNA products aimed at improving HIV treatment and prevention. The project involves developing plasmid products and supporting their production for clinical trials. The Administrative Core oversees the program's performance, ensuring that all goals are met through effective management, communication, and compliance. Patients may benefit from advancements in HIV vaccines and therapies that arise from this work.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV vaccines and treatments, improving health outcomes for individuals living with or at risk for HIV.
How similar studies have gone: Previous research in developing DNA-based vaccines for HIV has shown promise, indicating that this approach could lead to significant advancements.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Weiner, David B. — Wistar Institute
- Study coordinator: Weiner, David B.
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.